Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
20.11.2025
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended September 30, 2025. The condensed consolidated interim financial results are available on the Company’s website.
Nine-Month Financial Update
- Total revenues were €127.0 million compared to €116.6 million in the first nine months of 2024, an increase of 8.9%
- Product sales reached €119.4 million compared to €112.5 million in the first nine months of 2024, an increase of 6.2%
- Significant reduction in operating cash burn (€28.4 million in the first nine months of 2025 compared to €76.7 million in the first nine months of 2024)
- Net loss of €65.2 million compared to a net profit of €24.7 million in the first nine months of 2024, which included one-time net proceeds of €90.8 million from the sale of a Priority Review Voucher (PRV)